By the same authors

From the same journal

Thrombopoietin from beginning to end

Research output: Contribution to journalArticle

Published copy (DOI)

Author(s)

Department/unit(s)

Publication details

JournalBritish Journal of Haematology
DateE-pub ahead of print - 6 Feb 2014
DatePublished (current) - Apr 2014
Issue number2
Volume165
Number of pages10
Pages (from-to)259-68
Early online date6/02/14
Original languageEnglish

Abstract

In the two decades since its cloning, thrombopoietin (TPO) has emerged not only as a critical haematopoietic cytokine, but also serves as a great example of bench-to-bedside research. Thrombopoietin, produced by the liver, is the primary regulator of megakaryocyte progenitor expansion and differentiation. Additionally, as TPO is vital for the maintenance of haematopoietic stem cells, it can truly be described as a pan-haematopoietic cytokine. Since recombinant TPO became available, the molecular mechanisms of TPO function have been the subject of extensive research. Via its receptor, c-Mpl (also termed MPL), TPO activates a wide array of downstream signalling pathways, promoting cellular survival and proliferation. Due to its central, non-redundant role in haematopoiesis, alterations of both the hormone and its receptor contribute to human disease; congenital and acquired states of thrombocytosis and thrombocytopenia and aplastic anaemia as a result from dysregulated TPO expression or functional alterations of c-Mpl. With TPO mimetics now in clinical use, the story of this haematopoietic cytokine represents a great success for biomedical research.

Bibliographical note

© 2014 John Wiley & Sons Ltd.

    Research areas

  • Animals, Blood Platelets, Cloning, Molecular, Gene Expression Regulation, Hematopoietic Stem Cells, Humans, Receptors, Thrombopoietin, Signal Transduction, Thrombopoiesis, Thrombopoietin

Discover related content

Find related publications, people, projects, datasets and more using interactive charts.

View graph of relations